<DOC>
	<DOCNO>NCT01545245</DOCNO>
	<brief_summary>The primary objective study determine whether incidence atopic asthma three year old may suppress child born preterm infant prophylactically treat palivizumab respiratory syncytial ( RS ) virus infection infancy . The secondary objective determine whether incidence recurrent wheeze three year old may suppress child born preterm infant prophylactically treat palivizumab RS virus infection infancy .</brief_summary>
	<brief_title>Effects Preventive Treatment Respiratory Syncytial ( RS ) Virus Infection During Infancy Later Atopic Asthma Preterm Infants</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Sounds</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Infants bear July ~ December 2007 33~35 week gestation Infants administer least 3 dos palivizumab first 6 month life ( Palivizumab treat ) Infants administer dos palivizumab first 6 month life ( Palivizumab untreated ) Intrauterine growth retardation ( le 2.5SD ) Infants chronic lung disease ( CLD ) respiratory disease Infants receive mechanical ventilation Infants chronic heart disease ( CHD ) congenital anomaly ( immunodeficiency )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>atopic asthma</keyword>
	<keyword>recurrent wheeze</keyword>
	<keyword>preterm infant</keyword>
	<keyword>palivizumab</keyword>
	<keyword>respiratory syncytial virus</keyword>
	<keyword>RSV</keyword>
</DOC>